Vigonvita Life Sciences Co., Ltd. (HKG:2630)

Market Cap	11.74B
Revenue (ttm)	113.61M +762.9%
Net Income	-395.85M
EPS	-2.59
Shares Out	167.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	429,400
Open	75.55
Previous Close	75.45
Day's Range	70.05 - 76.65
52-Week Range	51.00 - 134.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 31, 2026

About Vigonvita Life Sciences

Vigonvita Life Sciences Co., Ltd., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its lead products include LV232, a first-in-class dual-target serotonin transporter/5-hydroxytryptamine 3 receptor modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the tre...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2013
• Employees: 315
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2630

Financial Performance

In 2025, Vigonvita Life Sciences's revenue was 102.10 million, an increase of 762.88% compared to the previous year's 11.83 million. Losses were -355.72 million, 68.3% more than in 2024.

Financial numbers in CNY